Effect of antibiotics on outcomes with systemic treatments for metastatic kidney cancer

The microbes in the gut (the gut microbiome) are a key part of our immune system. The use of antibiotics disrupts the gut microbiome and has been shown to make people susceptible to various illnesses. In this study, researchers investigated how antibiotics may influence response to treatment and clinical outcomes in people with metastatic renal […]

read more

The effect of antibiotic use on outcomes with kidney cancer drug treatments

A recent study has looked at the use of antibiotics with systemic drug treatments for renal cell carcinoma (RCC). The study investigated patients taking immune checkpoint inhibitors (146 patients), interferon-α (510 patients), mTOR inhibitors (660 patients) and VEGF targeted therapies (2,974 patients). The latter three groups were on phase II/III clinical trials, while the immunotherapy […]

read more

Effect of antibiotic use on outcomes with systemic therapies in metastatic kidney cancer

This study, published in European Urology Oncology this week, investigated the impact of antibiotic use on clinical outcomes in patients with metastatic renal cell carcinoma (RCC) treated with systemic anti-cancer drugs. The use of antibiotics alters the microbes living in our guts (gut microbiota), which is a key regulator of immune system. In the study, […]

read more

Effect of antibiotics on targeted therapy and immunotherapy for kidney cancer

The following is an interview with Dr Neeraj Agarwal, Associate Professor, Department of Internal Medicine (Medical Oncology), University of Utah, Salt Lake City, USA. Dr Agarwal talks about the effect of taking antibiotics before drug treatment for advanced/metastatic kidney cancer. Previous studies have shown that prior antibiotic use reduces the effectiveness of immune checkpoint inhibitors […]

read more
Showing all 4 results